HCV Detection among Blood Donors from 18 Provincial Blood Centers in China from 2018 to 2022

doi:10.3969/j.issn.1671-2587.2024.05.010

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2024, Vol. 26 ›› Issue (5): 638-644.DOI: 10.3969/j.issn.1671-2587.2024.05.010

Previous Articles Next Articles

HCV Detection among Blood Donors from 18 Provincial Blood Centers in China from 2018 to 2022

LI Yuwei¹, HUANG Xia², ZHOU Yuan³, LIU Ying⁴, WANG Lin⁵, ZOU Binbin⁶, LIU Humin⁷, MA Haili⁸, XU Tingting⁹, TANG Fei¹⁰, CAO Mingjing¹¹, HOU Linghua¹², LI Yujun¹³, HU Wenjia¹⁴, FENG Weiping¹⁵, LIU Yanyan¹⁶, DUAN Yong¹⁷, WEN Tao¹⁸, LI Mingxia¹⁹, QIU Yan²⁰

Baoji Blood Center, Shaanxi, 721000

Received:2024-07-02 Online:2024-10-20 Published:2024-09-20

Abstract

Abstract: Objective The data of hepatitis C virus (HCV) among blood donors in the service areas of provincial blood centers were analyzed. Methods Anti-HCV and HCV RNA data from 2018 to 2022 from first-time and repeat donors at 18 provincial blood HCV ELISA and anti-HCV ELISA negative RNA was analyzed. These was related to the year, blood center, and first-time and repeat donors. Results Between 2018 and 2022, the total unqualified rate of HCV decreased from 26.61/10 000 to 15.17/10 000 (χ²=717.71, P <0.01). The highest rate was 25.72/10 000 in western China and the lowest rate was 11.96/10 000 in eastern China. The unqualified rate of anti-HCV ELISA in first-time blood donors (30.50/10 000) was higher than that in repeat blood donors (7.42/10 000). The unqualified rate of anti-HCV ELISA negative HCV-RNA in each blood center ranged from 0 to 7.54/10 000. Conclusion The unqualified rate of HCV among blood donors in 18 centers decreased year by year. There are significant regional characteristics in the unqualified rate of HCV detection. Compared with the first-time blood donors, repeat donors were a lower-risk group. HCV RNA testing played an important role in blood safety.

Key words: Blood donors, Hepatitis C virus, Unqualified rate, Anti-HCV, ELISA, HCV, RNA

CLC Number:

R457

LI Yuwei, HUANG Xia, ZHOU Yuan, LIU Ying, WANG Lin, ZOU Binbin, LIU Humin, MA Haili, XU Tingting, TANG Fei, CAO Mingjing, HOU Linghua, LI Yujun, HU Wenjia, FENG Weiping, LIU Yanyan, DUAN Yong, WEN Tao, LI Mingxia, QIU Yan. HCV Detection among Blood Donors from 18 Provincial Blood Centers in China from 2018 to 2022[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 638-644.

References

[1] 中华人民共和国国家卫生健康委员会疾病预防控制局. 2020年全国法定传染病疫情概况[EB/OL].(2021—03—12)[2021-09-28].http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml.
[2] 文细毛,任南,李福琴,等. 2020年全国医院感染监控网丙型肝炎病毒感染监测报告[J]. 中国感染控制杂志,2024, 23(1):1-8.
[3] 邱艳,张评,高国静. 安全输血保障的策略[J]. 中华医院感染学杂志,2005,15(8):921-923.
[4] 陈立,张嫄. 输血传染病的预防策略[J]. 中华实验和临床病毒学杂志,2023,37(4):357-360.
[5] 田甜,邱艳,郭成城,等. 采供血机构执业比对信息管理系统的开发建设[J]. 临床输血与检验,2017,19(1):13-17.
[6] 郭成城,邱艳,张娟,等. 我国大陆采供血机构开展执业比对工作的现状[J]. 临床输血与检验,2017,19(1):4-7.
[7] ZHANG Y,CHEN L M,HE M.Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution[J]. Virol J,2017,14(1):41.
[8] 陈园生,李黎,崔富强,等. 中国丙型肝炎血清流行病学研究[J]. 中华流行病学杂志,2011,32(9):888-891.
[9] 庄辉. 中国丙型肝炎感染现状及防治对策研究报告[M].北京: 人民卫生出版社, 2018:3.
[10] 杨忠思,许守广,张微,等. 我国22家采供血机构献血人群HCV检测不合格情况调查分析[J]. 中华实验和临床病毒学杂志,2023,37(4):367-372.
[11] POSUWAN N,WANLAPAKORN N,SINTUSEK P,et al.Towards the elimination of viral hepatitis in Thailand by the year 2030[J]. J Virus Erad,2020,6(3):100003.
[12] OMIDKHODA A,RAZI B,ARABKHAZAELI A,et al.Trends and epidemiological analysis of hepatitis B virus, hepatitis C virus,human immunodeficiency virus,and human T-cell lymphotropic virus among Iranian blood donors:strategies for improving blood safety[J]. BMC Infect Dis,2020,20(1):736.
[13] WHO.hepatitis report WHO [EB/OL].[2024— 08—07].http://apps.who.int/iris/bitstream/10665/ 255016/1/9789241565455-eng.pdf?ua=1;2017. accessed July 2018.
[14] 陈冬梅,赵国庆,尹鲲,等. 2014—2020年血液成分制备技术的应用现状分析[J]. 北京医学,2023,45(4):351-355.
[15] 孙海泉,肖革新,郭莹,等. 中国2008—2012年丙肝流行规律及空间聚集性分析[J]. 中国公共卫生,2014,30(3):286-289.
[16] 马莹莹,李丽娟. 我国丙型病毒性肝炎分布综述[J]. 昆明学院学报,2020,42(6):98-101.
[17] SONG Y,BIAN Y,PETZOLD M,et al.Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China,2005 through 2010[J]. PLoS One,2014,9(4):e94528.
[18] 付萍,Liao Dan,吕运来,等. 中国5地无偿献血者HCV流行特征分析[J]. 中国输血杂志,2018,31(9):982-985.
[19] 王静,林红,周春,等. 南京地区无偿献血者HCV感染流行病学分析[J]. 中国输血杂志,2017,30(7):803-805.
[20] MOHAMMADALI F,POURFATHOLLAH A A.Changes in frequency of HBV,HCV,HIV and syphilis infections among blood donors in Tehran province 2005—2011[J]. Arch Iran Med,2014,17(9):613-620.
[21] 葛文超,吕永磊,陈明军,等.郑州地区无偿献血者血液筛查中丙型肝炎病毒残余风险的评估[J].中国输血杂志,2022, 35(05):546-549.
[22] 张丽云. 初次献血者与重复献血者4项血液检测结果的比较分析[J]. 国际检验医学杂志,2015,36(15):2258-2259.
[23] 邱艳,刘江. 良好献血者管理实践的评价与思考[J]. 中国输血杂志,2022,35(4):357-359.
[24] BAGOT K L,MURRAY A L,MASSER B M.How can we improve retention of the first-time donor? A systematic review of the current evidence[J]. Transfus Med Rev, 2016,30(2):81-91.
[25] 李永珍,甄志军. 间接法和夹心法HCV抗体诊断试剂盒的诊断性能评价与选择[J]. 临床肝胆病杂志,2014,30(10): 1042-1044.
[26] ZHANG L,ZHA Y,SHI L P,et al.Performance evaluation of two supplemental confirmatory assays of hepatitis C virus antibody[J]. Ann Blood,2021,6:12.
[27] 张佳娟,李平. 筛查献血者丙型肝炎病毒感染研究进展[J]. 实用肝脏病杂志,2015,18(1):109-112.
[28] BUSCH M P,KLEINMAN S H,JACKSON B,et al.Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases:Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors[J]. Transfusion,2000,40(2):143-159.
[29] DODD R Y,CROWDER L A,HAYNES J M,et al.Screening blood donors for HIV,HCV,and HBV at the American red cross:10-year trends in prevalence, incidence,and residual risk,2007 to 2016[J]. Transfus Med Rev,2020,34(2):81-93.
[30] O’BRIEN S F,YI Q L,FAN W L,et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services[J]. Transfusion,2007,47(2):316-325.
[31] 李凤园,袁玉华,潘彤. 2016—2020年天津市无偿献血者检测不合格情况及分布特征回顾性分析[J]. 中国输血杂志,2022,35(2):193-197.
[32] 杨琳琳,王艺芳,葛文超,等. 2012—2017年郑州地区无偿献血者核酸检测结果分析[J]. 实验与检验医学,2019, 37(3):546-548.
[33] 周丽君,张洪斌,毕新红,等. 乌鲁木齐市血液中心受委托集中化核酸检测结果分析[J]. 中国输血杂志,2016,29(9): 966-968.
[34] 吴敬林,周仲民. 核酸检测降低输血残余风险研究现状[J]. 齐齐哈尔医学院学报,2014,35(8):1198-1199.
[35] 谈维,英圣艳,成宁,等. 我国血站输血传播相关传染病标记物检测策略现状研究[J]. 中华实验和临床病毒学杂志, 2023,37(4):383-388.
[36] 赵冬雁,居兵,戚海,等. 国内20家采供血机构延迟献血的主要原因分析[J]. 中国输血杂志,2022,35(4):360-364.
[37] QIU Y,SHI L,WANG Y,et al.Risk factors for hepatitis C virus infection among blood donors in Beijing and implications for improving the pretesting donor screening process[J]. Transfusion,2008,48(6): 1207-1212.
[38] 安媛,修冰水,章金刚,等. HCV第一高变区的免疫学研究进展[J]. 中国医药生物技术,2009,4(2):134-136.
[39] FADDY H M,OSIOWY C,CUSTER B,et al.International review of blood donation nucleic acid amplification testing[J]. Vox Sang,2024,119(4):315-325.

HCV Detection among Blood Donors from 18 Provincial Blood Centers in China from 2018 to 2022

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	HU Junhua, HAN Jianfeng, WANG Peng, et al. Nucleic Acid Testing and Clinical Characteristics of Immunological Gray Zone for HBV, HCV, and HIV in a Multi-center Study [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 675-679.
[2]	JIANG Xiaojie, ZHANG Jingyi, MENG Yan, HUANG Chenjia. Current Situation Analysis and Strategic Exploration for Effective and Precise Recruitment of Blood Donors among University Students [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 680-682.
[3]	LI Suping, HU Xiaoyu, FANG Ye, CHEN Zhichao, JIANG Feifei, WANG Ting. Analysis on Characteristics of HEV Co-infection with HBV among Blood Donors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(4): 505-510.
[4]	WANG Guomei, YANG Jijun, LIU Tiemei. Advances in the Detection of Fetalmaternal Transfusion Syndrome and Related Disorders [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(3): 426-432.
[5]	WANG Siyun, LI Yibo, TAN Chunxia, LU Tao. Exploring the Mechanism of Psoralen on HepG2 Cells Based on Transcriptome Sequencing [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 35-41.
[6]	GUO Binhan, YE Ping, CHEN Jian, et al. Exploring the Effect of Red Blood Cell Storage Time on Endometrial Cancer Based on Bioinformatics [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 789-797.
[7]	HU Tingting, ZOU Binbin, ZHAO Feixue. Assessment of Residual Risk of HIV Transmission among Voluntary Blood Donors in Changsha Area [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 509-513.
[8]	ZHANG Wenjuan, DUAN Yong, JI Yuqiang, et al. LncRNA SNHG9 in Apheresis Platelets Following Storage [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 310-315.
[9]	GAO Zongshuai, ZHANG Haifang, LI Zhiqiang. Effect of Allogeneic Blood Transfusion on Plasma Exosomal MiRNA Expression in Patients with Traumatic Blood Loss [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 334-341.
[10]	LI Fengyuan, YUAN Yuhua, PAN Tong, et al. Analysis of HBV Infection Indexes in Repeated Non-Reactive Blood Donors with Nucleic Acid Test in Tianjin Area [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 395-400.
[11]	YANG Yan-yan, BAI Shun. Correlation Analysis of Antinuclear Antibody Profile Expression with HCV-RNA Load and HCV Genotype in Patients with Chronic Hepatitis C [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 767-772.
[12]	WANG Zhi-feng, SUN Hao, HU Dian, et al. LncRNAs ABHD11-AS1 Targets miR-133a to Upregulate EGFR Expression and Promote Ovarian Cancer cell Proliferation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(5): 574-581.
[13]	ZHANG Yuan-qin, XU Lu, MA Yi-ran, et al. Massive Fetomaternal Hemorrhage Caused by Maternal-fetal Blood Type Inconsistency:Diagnostic Value of Capillary Centrifugation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(5): 582-587.
[14]	FAN Ke-xin, ZHU Peng-hui, WANG Yun, et al. The Prediction Model of Fetomaternal Hemorrhage was Established on Machine Learning Algorithm [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(4): 427-432.
[15]	LU Da-peng, WANG Bao-long. Clinical Value Study of Serum MiRNAs as Potential Diagnostic Markers for Hepatocellular Carcinoma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(3): 343-348.